The global companion diagnostics market size was valued at USD 8.98 billion in 2025 and is projected to grow from USD 10.09 billion in 2026 to USD 25.57 billion by 2034, registering a CAGR of 12.33% during the forecast period from 2026 to 2034. North America dominated the companion diagnostics market with a market share of 42.5% in 2025.
Companion diagnostics are medical tests used to identify patients who are most likely to benefit from, or experience risks from, a specific therapeutic treatment. They analyze biomarkers such as genes, proteins, or other biological characteristics to support personalized treatment decisions. Companion diagnostics are widely used in oncology and other therapeutic areas to improve treatment effectiveness, reduce adverse reactions, and enable more precise patient care.
Download a Free Sample To learn more about this report,
Increasing Adoption of Multi-Biomarker Testing Platforms
The companion diagnostics market is shifting toward broader testing platforms capable of identifying multiple biomarkers from a single patient sample. This transition is being driven by the growing number of targeted therapies and the need to evaluate several molecular alterations during treatment selection. Multi-biomarker testing can reduce the need for repeated individual assays while helping clinicians identify eligible patients across multiple therapeutic pathways. This shift is increasing the importance of comprehensive molecular profiling capabilities in precision medicine.
Growing Shift Toward Liquid Biopsy-Based Companion Diagnostics
The market is increasingly incorporating liquid biopsy approaches that identify treatment-relevant biomarkers from blood samples rather than relying exclusively on tissue biopsies. Liquid-based testing can provide a less invasive method for detecting genomic alterations and can be particularly valuable when tissue samples are limited or difficult to obtain. Continued development of circulating tumor DNA testing is therefore expanding the role of blood-based companion diagnostics in precision oncology.
Expansion of Targeted Cancer Therapies Increases Demand for Companion Diagnostics
The increasing development of biomarker-targeted cancer therapies is directly expanding demand for companion diagnostics. These tests identify molecular or protein characteristics that help determine whether a patient is likely to benefit from a particular treatment. As pharmaceutical development increasingly focuses on biomarker-defined patient populations, diagnostic testing becomes an integral part of treatment selection and supports the expansion of the companion diagnostics market.
Growing Precision Medicine Adoption Supports Biomarker Testing
Healthcare systems are increasingly using molecular and biomarker information to guide treatment selection rather than relying solely on disease type or conventional clinical characteristics. Companion diagnostics provide the testing infrastructure required to identify relevant patient subgroups, supporting more targeted treatment strategies and increasing demand for molecular diagnostic technologies.
High Development Costs Increase the Financial Burden of Companion Diagnostics
Companion diagnostics often require analytical validation, clinical validation, regulatory submissions, laboratory infrastructure, and coordination with therapeutic development programs. When diagnostic and drug development must progress together, delays or changes in the therapeutic program can increase the financial and operational burden associated with the diagnostic. These requirements can restrict participation among smaller diagnostic developers.
Limited Access to Comprehensive Biomarker Testing Restricts Adoption
The effectiveness of companion diagnostics depends on access to appropriate testing laboratories, molecular pathology expertise, validated assays, and healthcare infrastructure. Regions with limited diagnostic capacity may struggle to implement sophisticated biomarker testing, restricting the number of patients who can be accurately matched with targeted therapies.
Expansion of Liquid Biopsy Applications Creates New Diagnostic Opportunities
The development of blood-based biomarker testing creates opportunities to expand companion diagnostics into situations where tissue samples are unavailable, insufficient, or difficult to obtain. Liquid biopsy can support repeated molecular assessment and may enable identification of genomic changes during disease progression, creating additional applications for companion diagnostic developers.
Expansion Into Non-Oncology Therapeutics Creates Additional Market Potential
Although oncology remains the primary application area, companion diagnostic technologies can also support treatment selection in other therapeutic fields where patient response depends on specific biological characteristics. Expanding biomarker research in autoimmune, infectious, neurological, and other diseases creates opportunities for diagnostic developers to establish new therapeutic-testing combinations.
Tumor Heterogeneity Can Reduce the Reliability of Biomarker-Based Treatment Selection
Cancer cells can differ substantially within the same tumor and can evolve during disease progression. This biological heterogeneity can make it difficult for a single tissue sample to accurately represent the full molecular profile of a patient's disease. As a result, companion diagnostic developers must account for variations in biomarker expression and genomic alterations when establishing test performance.
Regulatory Coordination Between Diagnostics and Therapeutics Can Delay Commercialization
Companion diagnostics frequently require coordination between diagnostic development and therapeutic development, creating dependencies between two regulatory pathways. Changes in clinical trial design, therapeutic indications, biomarker definitions, or diagnostic performance requirements can increase development complexity and extend commercialization timelines.
Polymerase Chain Reaction (PCR) Dominated the Market with 35.8% Share in 2025
The polymerase chain reaction (PCR) segment accounted for the largest share of the global companion diagnostics market at 35.8% in 2025, driven by its high sensitivity, established clinical utility, and widespread use in biomarker detection and patient stratification for targeted therapies.
Next-generation sequencing (NGS) is projected to register the fastest growth at a CAGR of 13.5% during 2026–2034, supported by increasing demand for comprehensive genomic profiling, advances in precision medicine, and the growing use of multi-biomarker testing. Immunohistochemistry remains an important technology for identifying protein biomarkers and guiding treatment decisions, while in situ hybridization continues to support molecular diagnostics by enabling the detection of specific genetic alterations. Other technologies also contribute to companion diagnostic testing across specialized clinical applications.
Request Customizationto receive a tailored report.
Oncology Dominated the Market with 66.8% Share in 2025
The oncology segment accounted for the largest share of the global companion diagnostics market at 66.8% in 2025, driven by the growing adoption of precision oncology, increasing cancer incidence, and the expanding availability of targeted therapies that require biomarker-based patient selection.
Autoimmune diseases continue to represent an important application area as companion diagnostics help identify patients who are more likely to respond to specific treatments. Cardiovascular diseases are increasingly incorporating molecular and genetic testing, while central nervous system disorders are benefiting from advances in biomarker identification and personalized medicine. Virology diseases also contribute to market growth through molecular testing and treatment-response assessment, while other indications continue to expand as precision medicine approaches become more widely adopted.
Speak to an Analystto discuss market opportunities.
North America accounted for a 42.5% companion diagnostics market share, valued at USD 3.82 billion in 2025. The region's growth is driven by increasing adoption of precision medicine, rising demand for biomarker-based testing, strong pharmaceutical and biotechnology research, and advanced healthcare infrastructure. Growing development of targeted therapies and increasing investments in oncology diagnostics continue to support regional companion diagnostics market growth.
The United States market accounted for the largest share of the North American market in 2025. Growth is driven by increasing adoption of precision medicine, expanding use of molecular and biomarker testing, rising development of targeted therapies, and the presence of leading pharmaceutical, biotechnology, and diagnostic companies. Strong clinical research capabilities and regulatory support further strengthen the country's market position.
Canada market is witnessing steady market growth due to increasing adoption of personalized medicine, expanding molecular diagnostic capabilities, rising investments in cancer research, and growing demand for biomarker-based testing to support targeted therapies.
Unlock Regional Insightsto access country-level data, & regional trends.
The European market accounted for 27.4% of the global companion diagnostics market, reaching USD 2.46 billion in 2025. Market growth is supported by increasing adoption of precision medicine, rising demand for molecular diagnostics, expanding pharmaceutical research, and growing use of biomarker testing in oncology and other therapeutic areas. Strong healthcare infrastructure and increasing investments in personalized treatment continue to drive regional demand.
The United Kingdom market is witnessing steady market growth owing to increasing adoption of precision medicine, expanding genomic and molecular testing programmes, rising investments in cancer diagnostics, and growing integration of companion diagnostics into targeted treatment strategies.
Germany market represents one of the largest markets in Europe, driven by advanced healthcare infrastructure, increasing adoption of molecular diagnostics, strong pharmaceutical research capabilities, and growing demand for biomarker-based testing and personalized therapies.
Asia Pacific market accounted for 21.6% of the global companion diagnostics market, valued at USD 1.94 billion in 2025, and is projected to register the fastest CAGR of 13.4% during the forecast period. The market is expanding due to increasing healthcare expenditure, rising adoption of precision medicine, growing investments in biotechnology and molecular diagnostics, and improving access to advanced testing technologies. Expanding cancer diagnostics and targeted therapy applications continue to support regional market growth.
Japan market is witnessing steady market growth due to increasing adoption of precision medicine, expanding molecular diagnostic testing, growing investments in oncology research, and rising use of biomarker-based companion diagnostics for targeted therapies.
China market accounted for the largest share of the Asia Pacific market in 2025. Growth is supported by increasing healthcare investments, expanding molecular diagnostics infrastructure, rising adoption of precision oncology, and growing development of targeted therapies and biomarker-based testing.
The Middle East & Africa market represented 3.4% of the global companion diagnostics market, totaling USD 0.31 billion in 2025. Rising investments in healthcare infrastructure, increasing adoption of molecular diagnostics, growing awareness of precision medicine, and expanding access to advanced cancer testing are supporting regional market growth.
The UAE market is a key market in the Middle East, driven by increasing investments in advanced healthcare infrastructure, expanding adoption of precision medicine, growing availability of molecular diagnostic technologies, and government initiatives supporting personalized healthcare.
Africa market is witnessing gradual market growth, supported by improving diagnostic infrastructure, increasing awareness of precision medicine, expanding access to molecular testing, and growing investments in cancer diagnosis and treatment. Countries such as South Africa, Kenya, and Nigeria are creating long-term growth opportunities for market participants.
Customize This Report to Match Your Strategic Objectives
Author's Details
Healthcare Lead
Debashree Bora is a strategic healthcare research professional with nearly eight years of hands on experience in market intelligence, encompassing primary research, secondary research, market estimation, and consulting engagements. She specializes in pharmaceutical, biotechnology, medical devices, healthcare services, clinical trials, and healthcare outsourcing sectors, providing actionable insights on evolving industry trends, regulatory landscapes, competitive dynamics, and market opportunities. Debashree’s research helps global clients evaluate market potential, identify growth opportunities, strengthen commercial strategies, and make informed business decisions.
CRISPR Gene Editing Market Size, Share, Growth, Analysis, 2034
Mass Spectrometry Market Size, Share, Growth, Analysis, 2034
Blood Testing Market Size, Share, Growth, Analysis, Report, 2034
3D Cell Culture Market Size, Share, Growth, Analysis, Report, 2034
3D Bioprinting Market Size, Share, Growth, Analysis, Report, 2034
United Kingdom Epigenetics Market Size, Trends, Top Share and Forecast to 2034
We are featured on:
sales@straitsresearch.com